Yorktown Management & Research Company’s Aurinia Pharmaceuticals AUPH Stock Holding History

Yorktown Management & Research Company’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$309K	Buy	+18,200	New	+$291K	0.19%	213

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

RWM

Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

NFG

Norris Financial Group Greenville, South Carolina $251M AUM 48.4% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Yorktown Management & Research Company's AUPH Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 18,200 shares worth $309K. The stake represents 0.19% of the portfolio and ranks #213 among its holdings.

124 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Yorktown Management & Research Company held 18,200 shares of Aurinia Pharmaceuticals worth $309K as of Q2 2026.
Aurinia Pharmaceuticals was a new Yorktown Management & Research Company position in Q2 2026.
Aurinia Pharmaceuticals made up 0.19% of Yorktown Management & Research Company's portfolio in Q2 2026, its #213 holding.
124 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.